News
NEXI
0.0001
NaN%
--
Weekly Report: what happened at NEXI last week (0810-0814)?
Weekly Report · 2d ago
Weekly Report: what happened at NEXI last week (0803-0807)?
Weekly Report · 08/10 10:23
Weekly Report: what happened at NEXI last week (0727-0731)?
Weekly Report · 08/03 10:22
Weekly Report: what happened at NEXI last week (0720-0724)?
Weekly Report · 07/27 10:27
Weekly Report: what happened at NEXI last week (0713-0717)?
Weekly Report · 07/20 10:23
Weekly Report: what happened at NEXI last week (0706-0710)?
Weekly Report · 07/13 10:25
Weekly Report: what happened at NEXI last week (0629-0703)?
Weekly Report · 07/06 10:29
Weekly Report: what happened at NEXI last week (0622-0626)?
Weekly Report · 06/29 10:24
Weekly Report: what happened at NEXI last week (0615-0619)?
Weekly Report · 06/22 10:34
Weekly Report: what happened at NEXI last week (0608-0612)?
Weekly Report · 06/15 10:34
Weekly Report: what happened at NEXI last week (0601-0605)?
Weekly Report · 06/08 10:30
Weekly Report: what happened at NEXI last week (0525-0529)?
Weekly Report · 06/01 10:35
Weekly Report: what happened at NEXI last week (0518-0522)?
Weekly Report · 05/25 10:39
Weekly Report: what happened at NEXI last week (0511-0515)?
Weekly Report · 05/18 10:38
Weekly Report: what happened at NEXI last week (0504-0508)?
Weekly Report · 05/11 10:35
Weekly Report: what happened at NEXI last week (0427-0501)?
Weekly Report · 05/04 10:32
Weekly Report: what happened at NEXI last week (0420-0424)?
Weekly Report · 04/27 10:35
Weekly Report: what happened at NEXI last week (0413-0417)?
Weekly Report · 04/20 10:31
NexImmune (NEXI) was downgraded to a Hold Rating at Citi
TipRanks · 04/14 05:56
Weekly Report: what happened at NEXI last week (0406-0410)?
Weekly Report · 04/13 10:35
More
Webull provides a variety of real-time NEXI stock news. You can receive the latest news about Neximmune, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NEXI
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.